Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
前收盤價
US$5.04
−US$0.09 · -1.75%
盤中時間採用ET。市場資料可能有所延遲。
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
日內區間
目前US$5.04
52週區間
目前US$5.04
盤中時間採用ET。市場資料可能有所延遲。
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
日內區間
目前US$5.04
52週區間
目前US$5.04
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | — | 12.5萬 USD | 12.5萬 USD |
| 毛利 | — | — | — | 12.5萬 USD | 12.5萬 USD |
| 研究與開發 | 3049.6萬 USD | 1931.4萬 USD | 2450.6萬 USD | 2078.7萬 USD | 1517.8萬 USD |
| 銷售、一般及管理費用 | 1777萬 USD | 1405.7萬 USD | 1388.5萬 USD | 1406萬 USD | 1067.3萬 USD |
| 營業費用 | 4826.6萬 USD | 3337.1萬 USD | 3839.1萬 USD | 3479.9萬 USD | 2585.1萬 USD |
| 利息收入 | 391.5萬 USD | 108.6萬 USD | 208.1萬 USD | 121.8萬 USD | — |
| 利息支出 | 211.9萬 USD | 209萬 USD | 259.5萬 USD | 170.8萬 USD | — |
| 折舊和攤銷 | 84.5萬 USD | 99萬 USD | 96萬 USD | 77.8萬 USD | 23.2萬 USD |
| 營業利益 | −4826.6萬 USD | −3337.1萬 USD | −3839.1萬 USD | −3467.4萬 USD | −2572.6萬 USD |
| 淨利 | −3818.2萬 USD | −5517.7萬 USD | −3793.9萬 USD | −1879.4萬 USD | −3612.4萬 USD |
公司資料更新於 2026年11月22日。
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$22.33
上漲空間 343.06%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1430.78萬0.00%6893億 USD0.03%US$340.02-3.52%
State Street SPDR S&P Biotech ETFXBI1146.09萬0.12%96.36億 USD0.35%US$140.18-2.73%
iShares Russell 2000 ETFIWM856.28萬0.01%715.37億 USD0.19%US$256.61-2.88%
Vanguard Extended Market ETFVXF670.14萬0.01%302億 USD0.05%US$211.44-3.21%
Vanguard Russell 2000 ETFVTWO309.93萬0.02%168億 USD0.06%US$103.76-2.76%
iShares Russell 2000 Growth ETFIWO282.68萬0.02%127.32億 USD0.24%US$320.43-3.57%
iShares Biotechnology ETFIBB236.4萬0.02%105.27億 USD0.44%US$199.54-2.05%
Schwab U.S. Small-Cap ETFSCHA189.21萬0.01%204.47億 USD0.03%US$30.51-2.83%
Vanguard Morningstar Total Stock Market ETFVTI
State Street SPDR S&P Biotech ETFXBI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
Vanguard Russell 2000 ETFVTWO
iShares Russell 2000 Growth ETFIWO
iShares Biotechnology ETFIBB
Schwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。